May 18, 2017
Reston, Va. – The Society of Nuclear Medicine and Molecular Imaging’s 2017 Annual Meeting will be held in Denver, Colorado, June 10-14. It will bring together more than 5,000 physicians, technologists, scientists and exhibitors from around the globe to share and learn about cutting-edge research, advance their knowledge through continuing education sessions, and network.
The focus is on science—improving patients’ lives by developing new methods to diagnose earlier and more accurately, delivering the most effective therapy for a specific patient’s disease, and monitoring and adjusting treatment to ensure optimum results. There are series of sessions for scientists, physicians, and technologists covering latest advances in the field, including the growing role of nuclear medicine and molecular imaging in precision medicine.
The Opening Plenary Session on Sunday, June 11, will feature theranostics. The Henry N. Wagner, Jr., MD, Lecture, titled “Theranostics: Looking Back and Moving Forward,” will be given by Richard Baum, MD, PhD. Johannes Czernin, MD, editor-in-chief of The Journal of Nuclear Medicine will then speak on “Imaging with a Purpose: The Future of Nuclear Medicine, Molecular Imaging and Therapy.”
The Opening Plenary will also introduce the society’s new Value Initiative, which addresses five critical domains that will guide the society’s strategic plan over the next several years: Quality of Practice, Research and Development, Workforce Pipeline and Lifetime Education, Advocacy, and Outreach.
SNMMI is an international organization that relies on collaboration across borders. This year, the annual meeting will highlight Germany’s latest advances in research, technology, and clinical practice.
The meeting will have more than 700 scientific oral sessions, as well as sessions on new tracers and applications, emerging technologies, a fluciclovine live reader training, updates on appropriate use criteria and coding and reimbursement, and Mo-99 production and availability. Three Meet-the-Author poster sessions will also be held, and the Exhibit Hall will be a one-stop showcase for cutting-edge molecular imaging devices, products, and services.
The CT and MRI Case Reviews, presented in collaboration with the University of Colorado Denver, will provide 12 hours of review over two consecutive days and include 52 CT studies and 48 MRI case studies.
In nuclear medicine and molecular imaging, the focus is always on the patient, and Patient Education Day, June 11, is an important part of the annual meeting. This year, it will include break-out sessions focusing on neuroendocrine tumors, prostate cancer, thyroid cancer, and Alzheimer’s Disease.
With many concurrent sessions, it’s not possible to attend everything of interest in person. The Virtual Poster Hall and Virtual Meeting will be available after the meeting for further education.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.